Skip to main content

What the FDA labels say about taking them together

Mavacamten and ranolazine

Mavacamten's FDA label of April 17, 2025 names ranolazine in its drug interactions section; the ranolazine labels PlainMeds reads (2) do not name mavacamten. The mavacamten label: “Avoid concomitant use of CAMZYOS in patients on disopyramide, ranolazine, verapamil with a beta blocker, or diltiazem with a beta blocker as these medications and combinations increase the risk of left ventricular …”

Check it at the source: the mavacamten FDA label on DailyMed (effective April 17, 2025, Myokardia, Inc.); the ranolazine FDA label on DailyMed (effective January 23, 2026, Glenmark Pharmaceuticals Inc., USA).

What does the mavacamten label say about ranolazine?

Mavacamten label, drug interactions

Avoid concomitant use of CAMZYOS in patients on disopyramide, ranolazine, verapamil with a beta blocker, or diltiazem with a beta blocker as these medications and combinations increase the risk of left ventricular systolic dysfunction and heart failure symptoms and clinical experience is limited [see Warnings and Precautions (5.1) ].

Source: FDA drug label (CAMZYOS), NDA214998 (Bristol), as published by Myokardia, Inc., effective April 17, 2025 (SPL set 669c936b-3ee6-4e36-8a22-79dd11b1255b), via openFDA; the full label on DailyMed

What does the ranolazine label say about mavacamten?

Ranolazine's label (effective January 23, 2026) and its 1 other brand-application label do not name mavacamten in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Ranolazine), Glenmark Pharmaceuticals Inc., USA, effective January 23, 2026 (SPL set 0cf58732-c242-49b0-8e3f-248778b4458d), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

0Mavacamten generic labelers
28Ranolazine generic labelers
MavacamtenRanolazine
Labeled forn/aAngina
Boxed warningYesNo
Pharmacy cost (NADAC)n/a$0.165 per tablet 500 mg tablet
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?